Trial Profile

An Open-Label Randomized Phase 3 Study of Capecitabine 6 months versus Capecitabine 12 months as Adjuvant Chemotherapy for Stage 3(Dukes'C) Colon Cancer Patients

Status: Completed

Phase of Trial: Phase III

Latest Information Update: 22 Mar 2019

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

11 Oct 2016 Status changed from active, no longer recruiting to completed, according to to final results presented at the 41st European Society for Medical Oncology Congress.
11 Oct 2016 Primary endpoint (Disease-free survival) has not been met, according to final results presented at the 41st European Society for Medical Oncology Congress.
11 Oct 2016 Final results of this study, presented at the 41st European Society for Medical Oncology Congress.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com